Many clinical trials, especially oncology trials, incorporate a high degree of cross-over, confounding overall survival data. The session will focus on the methods used to deal with treatment switching in PBAC submissions, and the explicit advice on this topic in Version 5 of the PBAC Guidelines. Attendees to this session will hear from two speakers each presenting from a different perspective; David Tamblyn, an experienced evaluator from the Adelaide HTA group, and Professor Andrew Wilson, PBAC Chair. A Q&A session will allow for plenty of time for informative discussion.
Chairperson: Emma Warren, Director, HERA consulting